D-0190-2025 Class II Ongoing
FDA drug recall D-0190-2025 was initiated by Rising Pharma Holding, Inc. on Dec 30, 2024 and is designated Class II. Reason for recall: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 244,460 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 15, 2025
- Initiation Date
- Dec 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 244,460 bottles
Product description
Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ
Reason for recall
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Distribution pattern
Nationwide
Code information
Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0190-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026